Combination Therapy Using Mycophenylate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis

Trial Profile

Combination Therapy Using Mycophenylate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2013

At a glance

  • Drugs Interferon beta-1a (Primary) ; Mycophenolate mofetil
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Mar 2013 Results with focus on efficacy and tolerability presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top